NCT04216082 - A Study of Anlotinib in Subjects With Advanced Malignancy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 1, 2015

Conditions

Advanced Malignancy

Interventions

DRUG

Anlotinib

Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing